AtriCure Past Earnings Performance

Past criteria checks 0/6

AtriCure has been growing earnings at an average annual rate of 7.1%, while the Medical Equipment industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 14.3% per year.

Key information

7.1%

Earnings growth rate

11.0%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate14.3%
Return on equity-6.5%
Net Margin-7.6%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Mar 14
Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues

Jan 21
Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Nov 29
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Sep 27
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

Aug 02
Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Jun 15
AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Apr 14
Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

Mar 02
Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

Feb 09
What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Dec 28
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

Sep 06
Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

Aug 02
An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

AtriCure: 5x Sales For A Series Of Impeding Losses? No Thanks

Jun 13

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Jun 08
Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

May 08
Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

Is AtriCure, Inc. (NASDAQ:ATRC) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 11
Is AtriCure, Inc. (NASDAQ:ATRC) Expensive For A Reason? A Look At Its Intrinsic Value

Is AtriCure (NASDAQ:ATRC) A Risky Investment?

Feb 18
Is AtriCure (NASDAQ:ATRC) A Risky Investment?

Why AtriCure, Inc. (NASDAQ:ATRC) Could Be Worth Watching

Jan 20
Why AtriCure, Inc. (NASDAQ:ATRC) Could Be Worth Watching

Robust Earnings May Not Tell The Whole Story For AtriCure (NASDAQ:ATRC)

Nov 11
Robust Earnings May Not Tell The Whole Story For AtriCure (NASDAQ:ATRC)

Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Oct 21
Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Revenue & Expenses Breakdown
Beta

How AtriCure makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:ATRC Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23399-3025874
30 Sep 23381-2524167
30 Jun 23366-2824162
31 Mar 23349-3823559
31 Dec 22330-4623157
30 Sep 22316-5622957
30 Jun 223035322154
31 Mar 222905221451
31 Dec 212745020549
30 Sep 212594519046
30 Jun 21243-5717445
31 Mar 21213-4915143
31 Dec 20207-4815143
30 Sep 20210-4614745
30 Jun 20212-5015745
31 Mar 20230-4616545
31 Dec 19231-3516741
30 Sep 19222-2315937
30 Jun 19216-2015035
31 Mar 19209-1714434
31 Dec 18202-2114035
30 Sep 18195-2013534
30 Jun 18187-2013033
31 Mar 18180-2712634
31 Dec 17175-2712134
30 Sep 17170-3311636
30 Jun 17166-3211137
31 Mar 17160-3410937
31 Dec 16155-3310536
30 Sep 16150-3610634
30 Jun 16143-3510232
31 Mar 16135-329729
31 Dec 15129-279126
30 Sep 15123-228523
30 Jun 15118-168322
31 Mar 15112-147820
31 Dec 14107-167819
30 Sep 1499-167417
30 Jun 1493-186815
31 Mar 1487-176514
31 Dec 1381-115713
30 Sep 1378-95013
30 Jun 1374-84712
31 Mar 1372-84512

Quality Earnings: ATRC is currently unprofitable.

Growing Profit Margin: ATRC is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ATRC is unprofitable, but has reduced losses over the past 5 years at a rate of 7.1% per year.

Accelerating Growth: Unable to compare ATRC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATRC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (8.7%).


Return on Equity

High ROE: ATRC has a negative Return on Equity (-6.53%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.